UT-ICON-HEALTH-&-FITNESS
11.1.2021 12:02:50 CET | Business Wire | Press release
iFit, a global leader in interactive connected fitness technology, today announced the upcoming release of iFit ActivePulse automatic heart rate training. iFit’s cutting edge technology uses complex algorithms so an iFit subscriber’s heart rate controls the treadmill in real time, automatically adjusting the speed and incline to maintain the optimal heart rate zone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005174/en/
iFit’s game-changing innovation removes the guesswork from heart rate training, by allowing a member’s heart rate to automatically scale and tailor iFit’s vast library of workouts to their individual fitness levels and goals. iFit has applied for patent protection on ActivePulse, which will be available on all iFit-controlled NordicTrack® , ProForm® and Freemotion® treadmills.
Until now, the benefits of heart rate training have hinged on how well a person is able to manually monitor and adjust their effort in order to remain in a particular heart rate zone. In contrast, iFit ActivePulse creates a real-time feedback loop between a user’s measured heart rate and the treadmill’s speed and incline.
iFit ActivePulse heart rate training keeps the user in their optimal zone, while enabling them to accomplish their fitness goals by targeting different heart rate zones.
“ActivePulse lets each iFit customer's heart rate personalize their treadmill workout without the complicated calculations and constant manual adjustments that have long been associated with heart rate training,” said Mark Watterson, President of iFit. “ActivePulse provides a workout that is catered not just to a member; it is catered to that member based on how their heart rate is functioning during the workout.”
Daily variables such as hydration, sleep, and stress have a direct impact on heart rate, therefore the effectiveness of a given workout can vary from one day to the next based on heart rate performance. iFit ActivePulse scales and tailors the intensity of any iFit program to optimize the workout based on their heart rate at that moment—even incorporating advanced algorithms to gradually “learn” their unique behavioral patterns over time.
Heart rate training—the concept of exercising within predetermined ranges (or “zones”) of a user’s maximum heart rate to achieve specific fitness goals—has been used by elite athletes and coaches around the world for more than 30 years. With various heart rate zones corresponding to fitness goals like building endurance, and promoting recovery, heart rate training is widely accepted as the most intelligent way to achieve consistent and measurable progress towards specific fitness goals.
iFit ActivePulse is compatible with leading Bluetooth® heart rate monitors with broadcast functionality, including the iFit SmartBeat™ forearm heart rate monitor, as well as third-party devices from brands including Polar®, Garmin®, Wahoo® and WHOOP®.
Included with all iFit memberships, ActivePulse will be available on all iFit-enabled NordicTrack, ProForm and Freemotion treadmills via an automatic iFit software update in January 2021. The feature will become available for stationary bikes, rowers, and ellipticals from NordicTrack, ProForm and Freemotion soon thereafter.
About iFit
iFit is the patented connected fitness platform that powers NordicTrack, ProForm and Freemotion equipment. ICON, the creator and owner of iFit, pioneered interactive fitness and was issued its first of many patents for its training technology in the early 2000s. Founded with the belief that the majority of consumers would benefit from an interactive, personal training experience at home, iFit’s trainer-led, streaming workouts are now trusted by millions of consumers around the world.
iFit offers workout options for every fitness level and interest—from bodyweight training, boxing, HIIT, yoga, Pilates and more—to connected fitness workouts on NordicTrack home equipment. Patented interactive technology allows iFit Trainers to create workouts for iFit members that automatically adjust the member’s incline, decline, speed and resistance in sync with iFit’s streaming workouts. iFit interactive content is available on NordicTrack, ProForm and Freemotion treadmills, stationary bikes, rowers, ellipticals, strength machines and the iFit app.
ICON Health & Fitness, Inc. is a global health and fitness leader and owner of iFit, NordicTrack, ProForm, Freemotion and other fitness brands. Based in Logan, Utah, the 43-year old company has a multi-decade heritage of innovation and quality. ICON currently holds more than 330 patents, with more than 80 pending, and its products are sold in 116 countries. iFit workouts are streamed in English, Spanish, French and Mandarin Chinese, with more languages planned for 2021.
Join the discussion @iFit , @NordicTrack and @ProForm
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom